https://www.selleckchem.com/products/sel120.html The heterogeneity of diffuse large B-cell lymphoma (DLBCL) acts as a main barrier to identify the genetic basis of the disease and the choice of treatment. Differentially expressed genes (DEGs) from three mRNA expression profile datasets were screened using GEO2R, and bioinformatics analysis was performed on the DEGs. A total of six upregulated and 13 downregulated DEGs were identified. Among these, two hub genes with a high degree of correlation were selected. FBN1 and TIMP1 were identified via STRING analysis and validated by GEPIA. FBN1 and TIMP1 were highly expressed in DLBCL tissues. FBN1 expression was significantly higher in patients of the Ann Arbor stage group (III-IV), with higher IPI score (3-5), and in the non-GCB group. Patients with high TIMP1 expression were more frequently associated with B symptoms, Ann Arbor stage (III-IV), higher IPI score (3-5) and were in the non-GCB group. Furthermore, FBN1 siRNA decreased FBN1 and TIMP1 expression and downregulation of TIMP1 attenuated TIMP1 expression but not of FBN1. Migration of DLBCL cells reduced when treated with either FBN1 or TIMP1 siRNA. Moreover, FBN1 or TIMP1 siRNA decreased the expression of Wnt target genes. Simultaneous overexpression of TIMP1 resulted in an increase in these proteins. This confirmed that both FBN1 and TIMP1 were positively associated with DLBCL progression. Further analysis revealed that FBN1/TIMP1 interaction could improve DLBCL cell migration and regulate the Wnt signaling pathway. Although the underlying mechanisms regarding the interaction between FBN1 and TIMP1 requires further clarification, they might be potential therapeutic targets for DLBCL therapy. Single-cell RNA sequencing (scRNA-seq) was recently adopted for exploring molecular programmes and lineage progression patterns of pathogenesis of important diseases. In this study, scRNA-seq was used to identify potential markers for chondrocytes in osteoarthritis (OA) and t